DRG2 and cancer: We thus determined whether DRG2-depleted cancer cells with enhanced PD-L1 expression have defects in suppressing T cell activity by co-culturing mouse splenic CD4+ T cells with IFN-γ-stimulated B16F10 cells (Fig. 3A).